Home › Triple-Negative Breast Cancer › Maryland
Triple-Negative Breast Cancer clinical trials in Maryland
18 studies for Triple-Negative Breast Cancer are looking for participants at sites in Maryland.
Cities in Maryland
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT07619534A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Holy Cross Hospital ( Site 0069), Silver Spring
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
- MedStar Southern Maryland Hospital Center ( Site 0100), Clinton
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06841354Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- United Theranostics, Glen Burnie
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT03606967PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06245889A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
- National Institutes of Health Clinical Center, Bethesda
Recruiting
Ages 18 to 120 · All sexes · Updated Aug 21, 2026 · NCT07067138A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 1035, Baltimore
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07327489Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- National Institute of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT05660083Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- United Theranostics, Glen Burnie
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT07311993A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- University of Maryland Medical Center (UMMC), Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 19, 2025 · NCT06568692First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 28, 2022 · NCT05627960From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.